Shots:
- Iolyx has granted Théa exclusive global rights (excl. Asia) to develop & commercialize ILYX-002 for Dry Eye Disease associated with systemic autoimmune disorders & other ocular surface conditions
- Iolyx will receive ~$280M in clinical, regulatory, & commercial milestones; tiered royalties up to ~21%; & R&D cost reimbursement. Iolyx will design P-III trials, handle manufacturing, & non-clinical work, while Théa will conduct P-III trials, secure regional approvals, & lead all commercial activities, incl. sales, marketing, & market access
- Additionally, Iolyx also raised a $15M Series B led by Frazier Life Sciences, with GC&H joining, to support its pipeline
Ref: GlobeNewswire | Image: Iolyx & Théa | Press Release
Related News: RemeGen Enters a Licensing Agreement with Santen Pharmaceutical for RC28-E to Treat Eye Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
